视力障碍患者糖尿病治疗管理的无障碍性。

Innovations in pharmacy Pub Date : 2024-08-21 eCollection Date: 2024-01-01 DOI:10.24926/iip.v15i3.6233
Cambrey Nguyen, Lisa Lim, Emily Conard, Arinze Nkemdirim Okere
{"title":"视力障碍患者糖尿病治疗管理的无障碍性。","authors":"Cambrey Nguyen, Lisa Lim, Emily Conard, Arinze Nkemdirim Okere","doi":"10.24926/iip.v15i3.6233","DOIUrl":null,"url":null,"abstract":"<p><p><i>Introduction</i>: According to the Centers for Disease Control, 11.8% of adults diagnosed with diabetes have severe vision difficulty or blindness, a complication of uncontrolled diabetes. The study evaluated the accessibility features of the most commonly used injectable products for diabetes and blood glucose monitors and obtained recommendations from manufacturers regarding use of these products in patients with visual disabilities. Additionally, accessibility of the medication guides was assessed using a checklist and screen reader. <i>Methods</i>: Selection of the most commonly prescribed insulin products, GLP-1 receptor agonist drugs, and blood glucose monitors were identified from the ClinCalc DrugStats database and ADA list. The accessibility features of these products were determined from the medication guides and verification of the information with the manufacturers were done in August 2022. All medication guides were then assessed using a checklist and tested with a screen reader for accessibility. Descriptive statistics were used to report the data. <i>Results</i>: No injectable products or glucose monitoring systems were fully accessible and manufacturers advised to use the product with caution and/or required assistance from a caregiver or family member. In evaluating the 14 medication guides for accessibility using the checklist, the most common issues were lack of structured headings to help with navigation, no descriptions for images, and tables did not have appropriate headers. <i>Conclusions</i>: Due to the lack of accessible features on diabetes medical devices and glucose monitoring systems, healthcare professionals can seek alternatives to assist this patient population to effectively manage their therapy.</p>","PeriodicalId":501014,"journal":{"name":"Innovations in pharmacy","volume":"15 3","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11524210/pdf/","citationCount":"0","resultStr":"{\"title\":\"Accessibility of Diabetes Therapy Management for Patients with Visual Impairment.\",\"authors\":\"Cambrey Nguyen, Lisa Lim, Emily Conard, Arinze Nkemdirim Okere\",\"doi\":\"10.24926/iip.v15i3.6233\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p><i>Introduction</i>: According to the Centers for Disease Control, 11.8% of adults diagnosed with diabetes have severe vision difficulty or blindness, a complication of uncontrolled diabetes. The study evaluated the accessibility features of the most commonly used injectable products for diabetes and blood glucose monitors and obtained recommendations from manufacturers regarding use of these products in patients with visual disabilities. Additionally, accessibility of the medication guides was assessed using a checklist and screen reader. <i>Methods</i>: Selection of the most commonly prescribed insulin products, GLP-1 receptor agonist drugs, and blood glucose monitors were identified from the ClinCalc DrugStats database and ADA list. The accessibility features of these products were determined from the medication guides and verification of the information with the manufacturers were done in August 2022. All medication guides were then assessed using a checklist and tested with a screen reader for accessibility. Descriptive statistics were used to report the data. <i>Results</i>: No injectable products or glucose monitoring systems were fully accessible and manufacturers advised to use the product with caution and/or required assistance from a caregiver or family member. In evaluating the 14 medication guides for accessibility using the checklist, the most common issues were lack of structured headings to help with navigation, no descriptions for images, and tables did not have appropriate headers. <i>Conclusions</i>: Due to the lack of accessible features on diabetes medical devices and glucose monitoring systems, healthcare professionals can seek alternatives to assist this patient population to effectively manage their therapy.</p>\",\"PeriodicalId\":501014,\"journal\":{\"name\":\"Innovations in pharmacy\",\"volume\":\"15 3\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-08-21\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11524210/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Innovations in pharmacy\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.24926/iip.v15i3.6233\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Innovations in pharmacy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.24926/iip.v15i3.6233","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

导言:根据美国疾病控制中心的数据,11.8% 的成年糖尿病患者有严重的视力障碍或失明,这是糖尿病未得到控制的并发症之一。这项研究评估了最常用的糖尿病注射产品和血糖监测仪的无障碍功能,并获得了制造商关于视力残疾患者使用这些产品的建议。此外,还使用核对表和屏幕阅读器对用药指南的无障碍性进行了评估。方法从 ClinCalc DrugStats 数据库和 ADA 列表中选择了最常用的处方胰岛素产品、GLP-1 受体激动剂药物和血糖监测仪。根据用药指南确定了这些产品的无障碍功能,并于 2022 年 8 月与制造商进行了信息核实。然后使用核对表对所有用药指南进行评估,并使用屏幕阅读器进行无障碍测试。使用描述性统计来报告数据。结果没有任何注射产品或血糖监测系统是完全无障碍的,制造商建议谨慎使用产品和/或需要护理人员或家庭成员的协助。在使用核对表对 14 种药物指南进行无障碍评估时,最常见的问题是缺乏有助于导航的结构化标题、图片没有说明以及表格没有适当的标题。结论:由于糖尿病医疗设备和血糖监测系统缺乏无障碍功能,医护人员可以寻求其他方法来帮助这类患者有效管理治疗。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Accessibility of Diabetes Therapy Management for Patients with Visual Impairment.

Introduction: According to the Centers for Disease Control, 11.8% of adults diagnosed with diabetes have severe vision difficulty or blindness, a complication of uncontrolled diabetes. The study evaluated the accessibility features of the most commonly used injectable products for diabetes and blood glucose monitors and obtained recommendations from manufacturers regarding use of these products in patients with visual disabilities. Additionally, accessibility of the medication guides was assessed using a checklist and screen reader. Methods: Selection of the most commonly prescribed insulin products, GLP-1 receptor agonist drugs, and blood glucose monitors were identified from the ClinCalc DrugStats database and ADA list. The accessibility features of these products were determined from the medication guides and verification of the information with the manufacturers were done in August 2022. All medication guides were then assessed using a checklist and tested with a screen reader for accessibility. Descriptive statistics were used to report the data. Results: No injectable products or glucose monitoring systems were fully accessible and manufacturers advised to use the product with caution and/or required assistance from a caregiver or family member. In evaluating the 14 medication guides for accessibility using the checklist, the most common issues were lack of structured headings to help with navigation, no descriptions for images, and tables did not have appropriate headers. Conclusions: Due to the lack of accessible features on diabetes medical devices and glucose monitoring systems, healthcare professionals can seek alternatives to assist this patient population to effectively manage their therapy.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信